Form 4: KEQU CEO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Kewaunee Scientific Corp's President and CEO, Thomas David Hull III, sold 658 shares of common stock in late December 2025 under a pre-arranged trading plan.
Summary
- Thomas David Hull III, President and CEO of Kewaunee Scientific Corp, reported sales of common stock.
- A total of 658 shares were sold across two transactions.
- On December 30, 2025, 29 shares were sold at $38 per share.
- On December 31, 2025, 629 shares were sold at a weighted average price of $37.66 per share, with prices ranging from $37.50 to $38.00.
- The transactions were conducted under a Rule 10b5-1 pre-arranged trading plan.
- Following these sales, Thomas David Hull III directly beneficially owns 35,177 shares of Kewaunee Scientific Corp common stock.
Sentiment
Score: 5
Explanation: Neutral. While insider selling can sometimes be viewed negatively, the execution under a Rule 10b5-1 plan suggests a pre-planned, non-discretionary transaction, which typically has a neutral market impact.
Negatives
- Insider selling, even under a Rule 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces management's direct equity stake in the company.
Future Outlook
NA
Industry Context
A Form 4 filing primarily reports insider transactions and does not typically provide broader industry context or trends.
Stakeholder Impact
- Shareholders: May interpret insider selling as a reduction in management's direct equity exposure, though the pre-arranged nature of a 10b5-1 plan generally mitigates concerns about discretionary selling based on new information. The number of shares sold is relatively small compared to the CEO's remaining holdings.
Key Dates
| Date | Description |
|---|---|
| 12/30/2025 | Sale of 29 shares of common stock by Thomas David Hull III. |
| 12/31/2025 | Sale of 629 shares of common stock by Thomas David Hull III. |
| 01/02/2026 | Date Form 4 was signed/filed. |
Recommendation
holdThe reported transactions are sales by the CEO under a Rule 10b5-1 plan, which are pre-scheduled and not indicative of new discretionary decisions based on recent company performance or outlook. The number of shares sold is relatively small compared to the CEO's remaining holdings. Therefore, this filing alone does not provide a strong signal for a 'buy' or 'sell' recommendation, suggesting a 'hold' position based solely on this information.
Keywords
Kewaunee Scientific Corp, KEQU, Insider Trading, Form 4, Stock Sale, CEO, Thomas David Hull III, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.